LONDON, May 14, 2012 /PRNewswire/ -- The increasing incidence of thrombosis, paralleled by the maturing life cycles of existing products, are motivating the need for novel alternatives. Establishing end-user confidence and ensuring cost-effectiveness pose significant challenges to market advancement. However, the launch of three blockbuster oral anticoagulants is projected to help the thrombosis therapeutics market address these challenges. It is also anticipated to help companies tackle competition from low cost generics.
New analysis from Frost & Sullivan (http://www.pharma.frost.com), Analysis of the European Thrombosis Therapeutics Market, finds that the market earned revenues of approximately $8.67 billion in 2010 and estimates this to reach approximately $13.01 billion in 2017 at a compound annual growth rate (CAGR) of 6.6 per cent from 2010-2017.
"The rising number of people suffering from thrombosis is resulting in higher demand for related therapeutics," notes Frost & Sullivan Research Analyst Deepika Pramod Chopda. "This, coupled with strong pipeline development, is pushing robust growth in the overall market."
About 4.5 million people in Europe are diagnosed with thrombosis annually, underlining the growing incidence of the disease. The result has been higher demand for treatment, complementing overall market growth. Approximately $3.46 billion was spent on R&D, indicative of vigorous efforts to develop innovative thrombotic drugs.
A key challenge has been the competition from generic manufacturers that are able to offer cost-effective equivalents to patented brands.
"The loss of patent rights of established thrombosis drugs in the early stages of the forecast period will contribute to the rise of generics," explains Deepika. "These low cost substitutes are likely to hinder the adoption of new and improved products."
Stringent approval procedures are also hampering market expansion. The European Medicines Agency (EMA) assesses several factors at every level of a drug's progress. This rigorous process limits the number of new medicines entering the market.
"Awareness raising through public healthcare forums and organisations about new developments and innovative treatment options will contribute towards establishing greater end-user confidence," concludes Deepika. "In the meantime, precautionary measures like adopting healthy lifestyle practices will help limit the incidence of the disease."
If you are interested in more information on this study, please send an e-mail with your contact details to Janique Morvan, Corporate Communications, at firstname.lastname@example.org.
Analysis of the European Thrombosis Therapeutics Market is part of the Pharmaceuticals & Biotechnology Growth Partnership Service programme, which also includes research in the following markets: European Biosimilars Market, Generic Pharmaceuticals Market – A Global Analysis and European Pharmaceutical and Biotech Contract Manufacturing Markets. All research included in subscriptions provide detailed market opportunities and industry trends that have been evaluated following extensive interviews with market participants.
About Frost & Sullivan
Frost & Sullivan, the Growth Partnership Company, enables clients to accelerate growth and achieve best-in-class positions in growth, innovation and leadership. The company's Growth Partnership Service provides the CEO and the CEO's Growth Team with disciplined research and best-practice models to drive the generation, evaluation, and implementation of powerful growth strategies. Frost & Sullivan leverages 50 years of experience in partnering with Global 1000 companies, emerging businesses and the investment community from more than 40 offices on six continents. To join our Growth Partnership, please visit http://www.frost.com.
Analysis of the European Thrombosis Therapeutics Market
Corporate Communications – Europe
P: +33 (0)1 42 81 20 37
M: +33 (0)6 79 22 41 42
|SOURCE Frost & Sullivan|
Copyright©2010 PR Newswire.
All rights reserved